Search results
Results from the WOW.Com Content Network
Hormone levels following a single intramuscular injection of EV/NETE (5 mg/50 mg) in healthy young men. [9] Testosterone levels were maximally suppressed by about 94%, to ~30 ng/dL, when measured at day 7. [9] EV/NETE is a combination of EV, an estrogen, and NETE, a progestogen with weak androgenic activity.
Estradiol valerate is and has been available in the form of vials and ampoules of oil solution for intramuscular injection in concentrations of 4, 5, 10, 20, and 40 mg/mL and in the form of oral tablets at doses of 0.5, 1, 2, and 4 mg per tablet.
Estradiol cypionate 5 mg + levonorgestrel butanoate 7 mg in an aqueous suspension [16] Estradiol benzoate 5 to 10 mg + norethisterone enanthate 50 to 100 mg [62] Mestranol 1.0–1.2 mg + norethisterone 10–12 mg in a microcrystalline aqueous suspension of defined particle sizes (125–177 μm) [25] [16] [62] [32] Ethinylestradiol ...
Testosterone levels were maximally suppressed by about 94%, to ~30 ng/dL, when measured at day 7 post-injection. [88] A single 200 mg intramuscular injection of norethisterone enanthate alone or in combination with 2 mg estradiol valerate has been found to produce a rapid, strong, and sustained decrease in gonadotropin and testosterone levels ...
Norethisterone and ethinylestradiol levels over 8 weeks after a single intramuscular injection of 200 mg NETE in premenopausal women. [ 35 ] A single intramuscular injection of 50 to 200 mg NETE in oil solution has been found to have a duration of action of 11 to 52 days in terms of clinical biological effect in the uterus and on body ...
In terms of dosage equivalence, norethisterone and NETA are typically used at respective dosages of 0.35 mg/day and 0.6 mg/day as progestogen-only contraceptives, and at respective dosages of 0.5–1 mg/day and 1–1.5 mg/day in combination with ethinylestradiol in combined oral contraceptives. [8]
A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication.
The average cost to a brand-name company of discovering, testing, and obtaining regulatory approval for a new drug, with a new chemical entity, was estimated to be as much as US$800 million in 2003 [15] and US$2.6 billion in 2014. [16]